ArticleCureus2026
Ripretinib-Induced Focal Segmental Glomerulosclerosis in a Patient With Gastrointestinal Stromal Tumor (GIST).
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ripretinib, a multikinase inhibitor, is used to treat refractory forms of advanced gastrointestinal stromal tumors. We describe a case of a 76-year-old male with a history of chronic kidney disease stage 3B/A3 (baseline creatine 2 mg/dL, urine protein/creatinine 3.5 gm/gm), diabetes, and aortic stenosis who presented with a sudden onset of lower extremity edema and weight gain of 20 lbs. Laboratory findings showed acute kidney injury (creatinine 2.5 mg/dL), hypoalbuminemia (albumin 2.4 g/dl), and nephrotic range proteinuria (urine protein/creatinine = 17 gm/gm). Renal biopsy showed focal segmental glomerulosclerosis. Ripretinib was stopped, and he was placed on high-dose steroids. After four months of prednisone, improvement in proteinuria and serum creatinine was seen. The clinical course suggested that podocyte injuries were induced by ripretinib, the disease process was presumptively responded to steroids, and the podocytopathy lasted after discontinuation of the medication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.